Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

134.38USD
26 May 2017
Change (% chg)

$-4.03 (-2.91%)
Prev Close
$138.41
Open
$138.46
Day's High
$139.36
Day's Low
$132.75
Volume
945,620
Avg. Vol
868,138
52-wk High
$153.14
52-wk Low
$71.75

INCY.OQ

Chart for INCY.OQ

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $27,517.59
Shares Outstanding(Mil.): 204.77
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.54 -- --
ROI: -9.69 -8.48 -5.42
ROE: -17.91 -11.31 -4.68

Merck, Incyte immunotherapy combination effective in lung cancer study

A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

May 18 2017

Merck, Incyte immunotherapy combination effective in lung cancer study

A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

May 17 2017

UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study

May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

May 17 2017

Merck, Incyte immunotherapy combination effective in lung cancer study

May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

May 17 2017

BRIEF-Incyte Q1 loss per share $0.96

* Incyte reports 2017 first-quarter financial results and updates on key clinical programs

May 04 2017

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

Apr 21 2017

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

April 21 A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

Apr 21 2017

BRIEF-Incyte CEO's 2016 compensation was $11.8 mln

* CEO Hervé Hoppenot's 2016 total compensation was $11.8 million versus $5.9 million in 2015 - sec filing Source text - http://bit.ly/2nWbbhV Further company coverage:

Apr 17 2017

U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant

WASHINGTON, April 14 The U.S. Food and Drug Administration on Friday declined to approve a new drug for rheumatoid arthritis made by Eli Lilly and Co and partner Incyte Corp, the companies said on Friday.

Apr 14 2017

BRIEF-Tetra Bio-Pharma, Intelgenx sign agreement for development, commercialization of Dronabinol XL tablet

* Tetra Bio-pharma and Intelgenx announce the signing of a definitive agreement for the development and commercialization of a Dronabinol XL tablet

Apr 03 2017

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.14 -0.02
Abbott Laboratories (ABT.N) $44.71 +0.76
Amgen, Inc. (AMGN.OQ) $155.01 -0.42
Biogen Inc (BIIB.OQ) $250.80 -2.17
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Sanofi SA (SASY.PA) €87.74 +0.43

Earnings vs. Estimates